MarketPulse

pediatric

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Regeneron

Sanofi and Regeneron Win FDA Nod for Dupixent in Young Children With Chronic Urticaria

FDA approves Dupixent for children ages 2-11 with chronic spontaneous urticaria, marking first biologic treatment for this pediatric population.
SNYREGNchronic spontaneous urticariaFDA approval
BenzingaBenzinga··Vandana Singh

AstraZeneca Splits on HPP Drug as COPD Candidate Advances

AstraZeneca's efzimfotase alfa succeeds in pediatric HPP trials but fails in adults. Meanwhile, tozorakimab meets COPD endpoints across smoker populations.
AZNPhase 3 trialsCOPD
BenzingaBenzinga··Vandana Singh

Eli Lilly's Eczema Drug Clears Phase 3 Pediatric Hurdle, Eyes Label Expansion

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.
LLYFDA approvalPhase 3 trial
BenzingaBenzinga··Vandana Singh

Takeda Stock Falls Despite Positive Pediatric UC Data for Entyvio

Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.
TAKPhase 3 trialpharmaceutical